文献速递白血病

ZIP10作为急性髓系白血病的潜在治疗靶点

ZIP10 as a potential therapeutic target in acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2025-06-30

研究利用急性髓系白血病(AML)细胞系和患者样本,发现恶性原始细胞锌水平显著升高伴血清锌降低,锌内流转运体ZIP6、ZIP9和ZIP10上调;体外实验显示锌对髓系细胞增殖、存活和分化阻滞至关重要;靶向ZIP10可损害锌摄取并抑制恶性细胞生长,提示其作为AML治疗靶点的潜力。

要点

  • AML恶性原始细胞锌水平显著升高,同时血清锌降低。
  • 锌内流转运体ZIP6、ZIP9和ZIP10在恶性原始细胞中上调。
  • 靶向ZIP10可损害锌摄取并减少恶性细胞生长。

核心结论

  • 靶向锌内流转运体ZIP10的治疗策略可能为AML患者提供新的治疗手段。

研究设计与样本

  • 研究利用AML细胞系和患者样本,并用Leukemia Mile(n=542)和BeatAML2.0研究(n=805)的数据验证结果。

主要发现

  • 与对照个体相比,恶性原始细胞锌水平显著升高,同时伴有血清锌降低。
  • 细胞锌水平升高伴随锌内流转运体ZIP6、ZIP9和ZIP10的上调。
  • 体外实验显示锌对髓系细胞增殖、存活和分化阻滞具有重要作用。
  • 靶向ZIP10导致锌摄取受损和恶性细胞生长减少。

关键数值与推荐

  • Leukemia Mile研究样本量n=542,BeatAML2.0研究样本量n=805。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukaemia (AML) is a haematopoietic malignancy that continues to demonstrate lapses in current treatment modalities as evidenced by therapy refractory disease, disease relapse and high rates of lethality. The influence of nutritional factors, including trace elements, on disease development and progression is not yet well understood. We utilized AML cell lines and patient samples to further investigate zinc homeostasis and the dependency of leukaemic cells on zinc. Compared to control individuals, we found significantly increased zinc levels in malignant blasts with concomitant serum hypozincaemia. Increased cellular zinc levels were accompanied by the upregulation of zinc influx transporters such as ZIP6, ZIP9 and ZIP10. Subsequent in vitro experiments showed the importance of zinc for myeloid cell proliferation, survival and block of differentiation. We validated our results with data from the Leukemia Mile (n = 542) and the BeatAML2.0 study (n = 805). Importantly, we identified ZIP10 (as one of the highly upregulated zinc transporters in malignant blasts) which, when targeted, resulted in impaired zinc uptake and decreased malignant cell growth. These findings suggest that therapeutic approaches that target the zinc influx transporter ZIP10 may offer novel means of treatment for patients suffering from AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rolles B, Chatain N, Görg R, et al. ZIP10 as a potential therapeutic target in acute myeloid leukaemia. Br J Haematol. 2025. PMID: 40583520. doi:10.1111/bjh.20229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。